Acalabrutinib demonstrates a favorable cardiovascular safety profile in CLL, with low cardiac failure rates compared to ibrutinib and chemoimmunotherapy. The selectivity of acalabrutinib reduces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results